Product Description
ABL1, also known as c-Abl, is a member of the non‑receptor tyrosine kinase family that plays a critical role in cell proliferation, differentiation, apoptosis, and cytoskeletal regulation. ABL1 is best characterized by its involvement in the BCR‑ABL1 fusion oncoprotein, resulting from a chromosomal translocation that drives the pathogenesis of chronic myeloid leukemia (CML) and Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL). Beyond its role in hematological malignancies, dysregulation of ABL1 signaling has been implicated in solid tumors, neurodegenerative disorders, and inflammatory diseases. The central role of ABL1, particularly in BCR‑ABL1-driven leukemogenesis, has established it as a highly validated target for cancer therapy, leading to the successful development of tyrosine kinase inhibitors such as imatinib and next‑generation agents for resistant mutations.
Screeningbio’s ABL1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying ABL1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: ABL1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the ABL1 kinase.
Data